Статья
Магнитно-резонансная томография сердца при гипертрофической кардиомиопатии: диагностические возможности, применение в клинической практике, прогностическая значимость
В настоящее время визуализирующие методы исследований играют центральную роль в оценке состояния сердечно-сосудистой системы. Магнитно-резонансная томография (МРТ) сердца заняла одну из главных позиций в диагностике и прогностической значимости гипертрофической кардиомиопатии (ГКМП). В статье представлен краткий обзор, посвященный как традиционным, так и новым сферам применения МРТ при ГКМП. Особое внимание уделено роли МРТ в отборе пациентов для хирургического лечения ГКМП.
1. Агеев Ф. Т., Габрусенко С. А., Постнов А. Ю. и др. Клинические рекомендации по диагностике и лечению кардиомиопатий (гипертрофическая). Кардиологический вестник. 2016;1:3-22.
2. Elliot PM, Anastasakis A, Borger MA, et al. ESC recommendations for the diagnosis and treatment of hypertrophic cardiomyopathy: a target group for the diagnosis and treatment of hypertrophic cardiomyopathy of the European Society of Cardiology. Eur Heart J. 2014;35:2733-79. doi:10.1093/eurheartj/ehu284.
3. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65(18):1915-28. doi:10.1016/j.jacc.2015.02.061.
4. Maron MS, Rowin EJ, Olivotto I, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(12):1399-409. doi:10.1016/j.jacc.2016.01.023.
5. Vatutin NT, Taradin GG, Maron MS. Hypertrophic cardiomyopathy: genetic changes, pathogenesis and pathophysiology. Russian Journal of Cardiology. 2014;(5):35-42. (In Russ.) Ватутин Н. Т., Тарадин Г. Г., Марон М. С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014;(5):35-42. doi:10.15829/1560-4071-2014-5-35-42.
6. Baxi AJ, Restrepo CS, Vargas D, et al. Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. RadioGraphics. 2016;36(2):33554. doi:10.1148/rg.2016150137.
7. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012; 52(4):857-64. doi:10.1016/j.yjmcc.2011.08.028. Epub 2011 Sep 5.
8. Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:407. doi:10.1161/CIRCULATIONAHA.110.985812. Epub 2011 Jun 13.
9. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13. doi:10.1186/1532-429X-14-13.
10. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). European Heart Journal. 2013;35(30):2010-20. doi:10.1093/eurheartj/eht439.
11. Varma PK, Neema PK. Hypertrophic cardiomyopathy: Part 1 — Introduction, pathology and pathophysiology. Annals of Cardiac Anaesthesia. 2014;17(2):118. doi:10.4103/09719784.129841.
12. Bogaert J, Olivotto I. MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology. 2014;273(2):329-48. doi:10.1148/radiol.14131626.
13. Chun EJ, Choi SI, Jin KN, et al. Hypertrophic cardiomyopathy: assessment with MR imaging and multidetector CT. RadioGraphics. 2010;30(5):1309-28. doi:10.1148/rg.305095074.
14. To AC, Dhillon A, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2011;4(10):1123-37.
15. Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy: relation to remodeling. J Am Coll Cardiol. 2009;53(3):284-91. doi:10.1016/j. jacc.2008.08.064.
16. Puntmann VO, Jahnke C, Gebker R, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(7):1016-22. doi:10.1016/j.amjcard.2010.05.036. Epub 2010 Aug 11.
17. Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. Circulation. 2015;132:292-8. doi:10.1161/CIRCULATIONAHA.114.014283.
18. Azevedo CF, Nigri M, Higuchi ML, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010;56:278-87. doi:10.1016/j.jacc.2009.12.074.
19. Sinitsyn VE, Mershina EA, Larina OM. Cardiac magnetic imaging opportunities in the diagnosis of cardiomyopathy. Clin. Experiment. Surg. Petrovsky J. 2014;1:54-63. (In Russ.) Синицын В. Е., Мершина Е. А., Ларина О. М. Возможности магнитно-резонансной томографиии в диагностике кардиомиопатии. Клин. и эксперимент. хир. Журн. им. акад. Б. В. Петровского. 2014;1:54-63.
20. Puntmann VO, Voigt T, Chen Z, et al. Native mapping of T1 in the differentiation of the normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6:475-84. doi:10.1016/j.jcmg.2012.08.08.019.
21. Dass S, Suttie JJ, Piechnik SK, et al. Characterization of myocardial tissue using magnetic resonance non-contrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:726-33. doi:10.1161/CIRCIMAGING.112.976738.
22. Sado DM, Flett AS, Banipersad SM, et al. Cardiovascular magnetic resonance measurement of extracellular myocardial volume in normal and pathological conditions. Heart. 2012;98:1436-41. doi:10.1136/heartjnl-2012-302346.
23. Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(3):415-22. doi:10.1161/CIRCIMAGING.112.000333. Epub 2013 Apr 2.
24. Sado DM, White SK, Pechnik SK, et al. Identification and assessment of AndersonFabry disease using T1 myocardial non-contrast mapping using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2013;6:392-8. doi:10.1161/CIRCIMAGING.112.000070.
25. Fontana M, Banypersad SM, Treibel TA, et al. Native mapping of T1 in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157-65. doi:10.1016/j.jcmg.2013.10.008.
26. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012 Apr;5(4):370-7. doi:10.1016/j.jcmg.2011.11.021.
27. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2011;142:153-203.
28. Spirito P, Binaco I, Poggio D, et al. Role of Preoperative Cardiovascular Magnetic Resonance in Planning Ventricular Septal Myectomy in Patients with Obstructive Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2019;123(9):151726. doi:10.1016/j.amjcard.2019.01.041.
29. Patel P, Dhillon A, Popovic ZB, et al. Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. Circulation. Cardiovascular Imaging. 2015;8(7):e003132-e003132. doi:10.1161/circimaging.115.003132.